(Q36081983)

12 August 2017

1 reference

title

The development and application of imatinib (English)

1 reference

12 August 2017

1 reference

ChEBI release 2020-05-28

Robin L Jones

1 reference

12 August 2017

Ian R Judson

series ordinal

1 reference

12 August 2017

language of work or name

English

0 references

publication date

1 March 2005

1 reference

Expert Opinion on Drug Safety

12 August 2017

published in

1 reference

12 August 2017

1 reference

12 August 2017

1 reference

12 August 2017

page(s)

183-191

1 reference

12 August 2017

cites work

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.2.183

Glioma-associated antigen expression in oligodendroglial neoplasms. Tenascin and epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.2.183

Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.2.183

The mouse type IV c-abl gene product is a nuclear protein, and activation of transforming ability is associated with cytoplasmic localization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.2.183

Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.2.183

The biology of chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.2.183

21 January 2018

Chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.2.183

Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.2.183

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.2.183

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.2.183

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.2.183

Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.2.183

High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.2.183

Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.2.183

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.2.183

Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.2.183

Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.2.183

Specific targeted therapy of chronic myelogenous leukemia with imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.2.183

Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.2.183

The histopathological differential diagnosis of gastrointestinal stromal tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.2.183

Gastrointestinal stromal tumors--definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.2.183

Gastrointestinal stromal tumors: recent advances in understanding of their biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.2.183

Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.2.183

Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.2.183

Gastrointestinal stromal tumours (GIST): biology and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.2.183

Biology of gastrointestinal stromal tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.2.183

Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.2.183

Mutations in exon 11 of c-Kit occur preferentially in malignant versus benign gastrointestinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.2.183

Mutations of c-kit JM domain are found in a minority of human gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.2.183

KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.2.183

Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.2.183

Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sa

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.2.183

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.2.183

Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.2.183

PDGFRA activating mutations in gastrointestinal stromal tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.2.183

Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.2.183

Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.2.183

Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.2.183

Treatment of hypereosinophilic syndrome with imatinib mesilate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.2.183

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.2.183

Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.2.183

Roots of clinical resistance to STI-571 cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.2.183

High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.2.183

BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.2.183

Phosphorylation and structure-based functional studies reveal a positive and a negative role for the activation loop of the c-Abl tyrosine kinase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.2.183

Strategies to overcome resistance to targeted protein kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.2.183

Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.2.183

21 January 2018

Identifiers

DOI

10.1517/14740338.4.2.183

1 reference

12 August 2017

1 reference